Disclosed herein are compositions useful for the treatment and/or prevention of various diseases and conditions, including a variety of infections, via internal administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of infections, including bacterial infections, viral infections, fungal infections, and the like. The compositions can be internally administered to a patient via at least one of: oral administration, pulmonary administration, subcutaneous administration, sublingual administration, ocular administration, otic administration, intravenous administration, inter-dermal administration, epidural administration, intraperitoneal administration, and intramuscular administration.

Disclosed herein are compositions useful for the treatment and/or prevention of various diseases and conditions, including a variety of infections, via internal administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of infections, including bacterial infections, viral infections, fungal infections, and the like. The compositions can be internally administered to a patient via at least one of: oral administration, pulmonary administration, subcutaneous administration, sublingual administration, ocular administration, otic administration, intravenous administration, inter-dermal administration, epidural administration, intraperitoneal administration, and intramuscular administration.

The invention provides new pyrazine derivatives of formula (I):

##STR00001##

or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

The present disclosure concerns a composition for an implantable pharmaceutical composition prepared from components consisting only of calcium sulfate α-hemihydrate in combination with two antibiotics, vancomycin and tobramycin, for the treatment of infection in bone and soft tissue.

The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.

The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.

The purpose of the present invention is to provide a solid pharmaceutical preparation of excellent stability and producibility, the preparation including, as an active ingredient, 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole. This solid pharmaceutical preparation contains 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole or a pharmaceutically acceptable salt thereof and a sugar alcohol and/or a cellulose derivative.

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome using a pyrazolylpyrimidine, e.g., a compound of Formula (I).

##STR00001##

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome using a pyrazolylpyrimidine, e.g., a compound of Formula (I).

##STR00001##

An oral pharmaceutical formulation using 4, 8-dihydroxy-5, 5, 7, 9, 13-pentamethyl-16-[1-methyl-2-(2-methyl-thiazole-4-yl)-ethenyl]]-oxacyclohexadec-13-ene-2,6-dione (utidelone) as an active ingredient, suitable for oral administration. The pharmaceutical formulation is a solid formulation such as tablets and capsules, and the pharmaceutical dosage form has good stability, in vitro dissolution behavior, and bioavailability.